Breast cancer is one of the most common malignancies, often with complicated etiology and poor clinical outcome. In recent years, a critical role has emerged for the WW domain-containing oxidoreductase (WWOX) in breast cancer. WWOX is a tumor suppressor; it is deleted or attenuated in 29–63.2% of breast cancer tissues and is associated with a poor prognosis of breast cancer patients. WWOX heterozygous knockout mice show a higher incidence of mammary tumors and impaired branching morphogenesis. At the molecular level, WWOX interacts with AP2γ, ErbB4, SMAD3, and WBP2 suppressing their transcription activities in breast cancer cell lines. This review provides comprehensive insights into the current knowledge of WWOX activities in the pathogenesis and endocrine therapy of breast cancer.
DillonLWBurrowAAWangYH. DNA instability at chromosomal fragile sites in cancer. Curr Genomics2010; 11: 326–37.
2.
LukusaTFrynsJP. Human chromosome fragility. Biochim Biophys Acta2008; 1779: 3–16.
3.
DurkinSGGloverTW. Chromosome fragile sites. Annu Rev Genet2007; 41: 169–92.
4.
PopescuNC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett2003; 192: 1–17.
5.
AqeilanRIDonatiVGaudioENicolosoMSSundvallMKorhonenALundinJIsolaJSudolMJoensuuHCroceCMEleniusK. Association of Wwox with ErbB4 in breast cancer. Cancer Res2007; 67: 9330–6.
6.
AqeilanRIPalamarchukAWeigelRJHerreroJJPekarskyYCroceCM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res2004; 64: 8256–61.
7.
AqeilanRIPekarskyYHerreroJJPalamarchukALetofskyJDruckTTrapassoFHanSYMelinoGHuebnerKCroceCM. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA2004; 101: 4401–6.
8.
GaudioEPalamarchukAPalumboTTrapassoFPekarskyYCroceCMAqeilanRI. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res2006; 66: 11585–9.
9.
KurekKCDel MareSSalahZAbdeenSSadiqHLeeSHGaudioEZanesiNJonesKBDeYoungBAmirGGebhardtMWarmanMSteinGSSteinJLLianJBAqeilanRI. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res2010; 70: 5577–86.
AqeilanRIHaganJPde BruinARawahnehMSalahZGaudioESiddiquiHVoliniaSAlderHLianJBSteinGSCroceCM. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology2009; 150: 1530–5.
12.
AqeilanRITrapassoFHussainSCostineanSMarshallDPekarskyYHaganJPZanesiNKaouMSteinGSLianJBCroceCM. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA2007; 104: 3949–54.
13.
ChangNSSchultzLHsuLJLewisJSuMSzeCI. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene2005; 24: 714–23.
14.
MahajanNPWhangYEMohlerJLEarpHS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res2005; 65: 10514–23.
15.
AqeilanRIHassanMQde BruinAHaganJPVoliniaSPalumboTHussainSLeeSHGaurTSteinGSLianJBCroceCM. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem2008; 283: 21629–39.
16.
ShenZWenXFLanFShenZZShaoZM. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res2002; 8: 2085–90.
17.
Ludes-MeyersJHKilHParker-ThornburgJKusewittDFBedfordMTAldazCM. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One2009; 4: e7775–e7775.
18.
AbdeenSKDel MareSHussainSAbu-RemailehMSalahZHaganJRawahnehMPuXARussellSSteinJLSteinGSLianJBAqeilanRI. Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol2013; 228: 1377–82.
19.
NunezMILudes-MeyersJAldazCM. WWOX protein expression in normal human tissues. J Mol Histol2006; 37: 115–25.
20.
GulerGUnerAGulerNHanSYIliopoulosDMcCuePHuebnerK. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int2005; 55: 471–8.
21.
EkizogluSMuslumanogluMDalayNBuyruN. Genetic alterations of the WWOX gene in breast cancer. Med Oncol2012; 29: 1529–35.
22.
WangXChaoLMaGChenLZangYSunJ. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol2011; 137: 271–8.
23.
DriouchKPrydzHMoneseRJohansenHLidereauRFrengenE. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene2002; 21: 8–8.
24.
PluciennikEKusinskaRPotemskiPKubiakRKordekRBednarekAK. WWOX—the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol2006; 32: 153–7.
25.
NunezMIRosenDGLudes-MeyersJHAbbaMCKilHPageRKlein-SzantoAJGodwinAKLiuJMillsGBAldazCM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer2005; 5: 64–64.
26.
LanCChenggangWYulanBXiaohuiDJunhuiZXiaoW. Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study. Int J Gynecol Pathol2012; 31: 125–32.
27.
GulerGHimmetogluCJimenezREGeyerSMWangWPCostineanSPilarskiRTMorrisonCSurenDLiuJChenJKamalJShapiroCLHuebnerK. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat2011; 129: 421–32.
28.
GulerGUnerAGulerNHanSYIliopoulosDHauckWWMcCuePHuebnerK. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer2004; 100: 1605–14.
29.
GulerGHuebnerKHimmetogluCJimenezRECostineanSVoliniaSPilarskiRTHayranMShapiroCL. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer2009; 115: 899–908.
30.
Reis-FilhoJSTuttAN. Triple negative tumours: a critical review. Histopathology2008; 52: 108–18.
31.
GluzOLiedtkeCGottschalkNPusztaiLNitzUHarbeckN. Triple-negative breast cancer—current status and future directions. Ann Oncol2009; 20: 1913–27.
32.
KrishnamurthySPoornimaRChallaVRGoudYG. Triple negative breast cancer—our experience and review. Indian J Surg Oncol2012; 3: 12–6.
33.
DriouchKPrydzHMoneseRJohansenHLidereauRFrengenE. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene2002; 21: 1832–40.
34.
GourleyCPaigeAJTaylorKJWardCKuskeBZhangJSunMJanczarSHarrisonDJMuirMSmythJFGabraH. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res2009; 69: 4835–42.
35.
BosherJMTottyNFHsuanJJWilliamsTHurstHC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene1996; 13: 1701–7.
36.
deConinckECMcPhersonLAWeigelRJ. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol1995; 15: 2191–6.
37.
SundvallMIljinKKilpinenSSaraHKallioniemiOPEleniusK. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia2008; 13: 259–68.
38.
GoumansMJLebrinFValdimarsdottirG. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med2003; 13: 301–7.
39.
FergusonBWGaoXZelazowskiMJLeeJJeterCRAbbaMCAldazCM. The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer2013; 13: 12–12.
40.
HsuLJSchultzLHongQVan MoerKHeathJLiMYLaiFJLinSRLeeMHLoCPLinYSChenSTChangNS. Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem2009; 284: 16049–59.
41.
LumachiFLuisettoGBassoSMBassoUBrunelloACamozziV. Endocrine therapy of breast cancer. Curr Med Chem2011; 18: 513–22.
42.
OrlandoaLSchiavoneaPFedeleaPCalvaniaNNacciaARizzoaPMarinoaAD’AmicoaMSponzielloaFMazzoniECinefraaMFaziobNMaiellocESilvestrisdNColuccidGCinieriaS. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev2010; 36S3: 64–71.
43.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet1998; 351: 1451–67.
44.
ShiauAKBarstadDLoriaPMChengLKushnerPJAgardDAGreeneGL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell1998; 95: 927–37.
45.
Gothlin EremoAWegmanPStalONordenskjoldBFornanderTWingrenS. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncol Rep2013; 29: 1467–74.
46.
GulerGIliopoulosDGulerNHimmetogluCHayranMHuebnerK. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res2007; 13: 6115–21.
47.
SalahZAqeilanRHuebnerK. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol2010; 6: 249–59.
48.
McDonaldCBBuffaLBar-MagTSalahZBhatVMiklesDCDeeganBJSeldeenKLMalhotraASudolMAqeilanRINawazZFarooqA. Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors. J Mol Biol2012; 422: 58–74.
49.
DhananjayanSCRamamoorthySKhanOYIsmailASunJSlingerlandJO’MalleyBWNawazZ. WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol2006; 20: 2343–54.
